The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells

Blood

Volumn 101, Issue 2, 2003, Pages 624-632

  Tonks, Alex ^a   Pearn, Lorna ^a   Tonks, Amanda J ^a   Pearce, Laurence ^a   Hoy, Terry ^a   Phillips, Sarah ^a   Fisher, Janet ^a   Downing, James R ^a   Burnett, Alan K ^a   Darley, Richard L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; CD36 ANTIGEN; ERYTHROPOIETIN; GLYCOPHORIN A; MICROSOMAL AMINOPEPTIDASE;

ACUTE GRANULOCYTIC LEUKEMIA; AML1 ETO FUSION GENE; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL RENEWAL; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; ERYTHROID CELL; ERYTHROPOIESIS; FUSION GENE; GENE EXPRESSION; GROWTH INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMOGENESIS; LIQUID CULTURE; MITOSIS INHIBITION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE;

EID: 0037438515     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1732     Document Type: Article

References (54)

1. Nucifora G, Rowley JD. The AML1 and ETO genes in acute myeloid leukemia with a t(8;21). Leuk Lymphoma. 1994;14:353-362.
2. Langabeer SE, Walker H, Rogers JR, et al. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials: MRC Adult Leukaemia Working Party. Br J Haematol. 1997;99:925-928.
3. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
4. Mitelman F, Heim S. Quantitative acute leukemia cytogenetics. Genes Chromosomes Cancer. 1992;5:57-66.
5. Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol. 1993;13:6336-6345.
6. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996;87:697-708.
7. Uchida H, Zhang J, Nimer SD. AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol. 1997;158:2251-2258.
8. Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene. 1999;18:1015-1022.
9. Britos-Bray M, Friedman AD. Core binding factor cannot synergistically activate the myeldperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol. 1997;17:5127-5135.
10. Zhang DE, Fujioka K, Hetherington CJ, et al. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBp2/CBF (AML1). Mol Cell Biol. 1994;14:8085-8095.
11. Oelgeschlager M, Nuchprayoon I, Luscher B, Friedman AD. C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol. 1996;16:4717-4725.
12. Sun W, Graves BJ, Speck NA. Transactivation of the Moloney murine leukemia virus and T-cell receptor β-chain enhancers by cbfand ets requires iritact binding sites for both proteins. J Virol. 1995;69:4941-4949.
13. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolatioh of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80:1825-1831.
14. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88:10431-10434.
15. Miyoshi H, Kozu T, Shimizu K, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 1993;12:2715-2721.
16. Downing JR, Higuchi M, Lenny N, Yeoh AE. Alterations of the AML1 transcription factor in human leukemia. Semin Cell Dev Biol. 2000;11:347-360.
17. Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol. 1999;106:296-308.
18. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1 B-dependent transcriptional activation. Mol Cell Biol. 1995;15:1974-1982.
19. Sakakura C, Yamaguchi-Iwai Y, Satake M, et al. Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide. Proc Natl Acad Sci U S A. 1994;91:11723-11727.
20. Ahn MY, Huang G, Bae SC, Wee HJ, Kim WY, Ito Y, Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. Proc Natl Acad Sci U S A. 1998;95:1812-1817.
21. Okuda T, Cai Z, Yang S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91:3134-3143.
22. Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet. 1997;15:303-306.
23. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
24. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93:3444-3449.
25. Niki M, Okada H, Takano H, et al. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. Proc Natl Acad Sci U S A. 1997;94:5697-5702.
26. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeadon JE, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63-74.
27. Rhoades KL, Hetherington CJ, Harakawa N, et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000;96:2108-2115.
28. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002;99:15-23.
29. Yuan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A. 2001;98:10398-10403.
30. Grignani F, Kinsella T, Mencarelli A, et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 1998;58:14-19.
31. Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene. 1999;18:1701-1710.
32. Horan PK, Slezak SE. Stable cell membrane labelling. Nature. 1989;340:167-168.
33. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 1997;27:1-20.
34. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991;77:2031-2036.
35. Freyssinier JM, Lecoq-Lafon C, Amsellem S, et al. Purification, amplification and characterization of a population of human erythroid progenitors. Br J Haematol. 1999;106:912-922.
36. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67.
37. Yashige H, Horiike S, Taniwaki M, Misawa S, Abe T. Micronuclei and nuclear abnormalities observed in erythroblasts in myelodysplastic syndromes and in de novo acute leukemia after treatment. Acta Haematol. 1999;101:32-40.
38. + cells. J Exp Med. 1997;185:1337-1347.
39. de Wolf JT, Muller EW, Hendriks DH, Halle RM, Vellenga E. Mast cell growth factor modulates CD36 antigen expression on erythroid progenitors from human bone marrow and peripheral blood associated with ongoing differentiation. Blood. 1994;84:59-64.
40. Van Schravendijk MR, Handunnetti SM, Barnwell JW, Howard RJ. Normal human erythrocytes express CD36, an adhesion molecule of monocytes, platelets, and endothelial cells. Blood. 1992;80:2105-2114.
41. Ziegler BL, Muller R, Valtieri M, et al. Unicellular-unilineage erythropoietic cultures: molecular analysis of regulatory gene expression at sibling cell level. Blood. 1999;93:3355-3368.
42. Okumura N, Tsuji K, Nakahata T. Changes in cell surface antigen expressions during proliferation and differentiation of human erythroid progenitors. Blood. 1992;80:642-650.
43. Harada Y, Harada H, Downing JR, Kimura A. A hematopoietic-specific transmembrane protein, Art-1, is possibly regulated by AML1. Biochem Biophys Res Commun. 2001;284:714-722.
44. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol. 2001;21:5577-5590.
45. Amann JM, Nip J, Strom DK et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol. 2001;21:6470-6483.
46. Lou J, Cao W, Bernardin F, Ayyanathan K, Rauscher FJ III, Friedman AD. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene. 2000;19:2695-2703.
47. Armesilla AL, Calvo D, Vega MA. Structural and functional characterization of the human CD36 gene promoter: identification of a proximal PEBP2/CBF site. J Biol Chem. 1996;271:7781-7787.
48. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A. 2000;97:7521-7526.
49. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996;87:4789-4796.
50. Papayannopoulou T, Abkowitz J. Biology of erythropoiesis, erythroid differentiation, and maturation. In: Hoffman R, ed. Haematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 1991:252-263.
51. Yamasaki H, Era T, Asou N, et al. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia. Leukemia. 1995;9:1147-1153.
52. Haferlach T, Bennett JM, Loffler H, et al. Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. Leuk Lymphoma. 1996;23:227-234.
53. Taj AS, Ross FM, Vickers M, et al. t(8;21) myelodysplasia, an early presentation of M2 AML. Br J Haematol. 1995;89:890-892.
54. Perry C, Eldor A, Soreq H. RUNX1/AML1 in leukemia: disrupted association with diverse protein partners. Leuk Res. 2002;26:221-228.